Research programme: fibrotic disease therapeutics - Evotec/Fibrocor

Drug Profile

Research programme: fibrotic disease therapeutics - Evotec/Fibrocor

Latest Information Update: 06 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fibrocor Therapeutics
  • Developer Evotec AG; Fibrocor Therapeutics
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Fibrosis

Most Recent Events

  • 17 Jan 2017 Preclinical trials in Fibrosis in Canada before January 2017
  • 17 Jan 2017 Fibrocor Therapeutics and Evotec agree to develop fibrotic therapeutics for Fibrosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top